PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-263.73%
Negative net income growth while AGEN stands at 212.41%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
304.86%
Well above AGEN's 270.83% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
166.93%
AP growth of 166.93% while AGEN is zero at 0.00%. Bruce Berkowitz would see a moderate difference that might matter for short-term liquidity if expansions are large.
1056.93%
Lower 'other working capital' growth vs. AGEN's 30199.82%. David Dodd would see fewer unexpected short-term demands on cash.
No Data
No Data available this quarter, please select a different quarter.
-36.01%
Negative yoy CFO while AGEN is 369.63%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both yoy lines negative, with AGEN at -100.00%. Martin Whitman suspects a cyclical or strategic rationale for cutting extra invests in the niche.
-104.63%
Both yoy lines negative, with AGEN at -100.00%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.